Collectively, the application of novel targeted inhibition of the NLRP3/caspase 1/GSDMD axis holds significant promise as a therapeutic strategy for mitigating myocardial injury and inflammation in IHD, as evidenced by the robust protective effects observed in both in vitro and in vivo models. The gene discussed is NLRP3; the disease is myocardial ischemia.